N
ATNM icon

Nuveen’s Actinium Pharmaceuticals ATNM Stock Holding History

Nuveen’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-148,560
Closed -$239K – 3284
2025
Q1 		$239K Hold
148,560
– – ﹤0.01% 3082
2024
Q4 		$187K Buy
148,560
+49,214
+50% +$76.4K ﹤0.01% 3217
2024
Q3 		$187K Sell
99,346
-70,820
-42% -$280K ﹤0.01% 3236
2024
Q2 		$1.26M Buy
170,166
+70,820
+71% +$583K ﹤0.01% 2617
2024
Q1 		$778K Hold
99,346
– – ﹤0.01% 2802
2023
Q4 		$505K Hold
99,346
– – ﹤0.01% 2999
2023
Q3 		$588K Hold
99,346
– – ﹤0.01% 2786
2023
Q2 		$737K Buy
+99,346
New +$845K ﹤0.01% 2791

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Nuveen's ATNM Position: Q2 2025 in Review

Nuveen sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 148,560 shares — an estimated $239K sold.

Nuveen first reported a position in ATNM in Q2 2023 and held it in 8 quarters. The position peaked at $1.26M in Q2 2024. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Nuveen reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 148,560 Actinium Pharmaceuticals shares in Q2 2025, an estimated $239K.
  • Nuveen first reported a position in Actinium Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Nuveen's Actinium Pharmaceuticals position peaked at $1.26M in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.